All Oncology News

Epcoritamab-based treatment yielded durable remissions in patients with follicular lymphoma, both as first-line induction and maintenance.

Phase 1 data showed that LP-184 displayed an acceptable safety profile and was well-tolerated in heavily-pretreated patients with advanced solid tumors.

Frontline dasatinib was linked to frequent T315I mutations at relapse in Ph+ ALL, while ponatinib showed fewer resistance mutations and favorable outcomes.

Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.

Tafasitamab plus lenalidomide and rituximab has been approved by the European Commission in relapsed/refractory follicular lymphoma.

Signatera MRD positivity predicted improved DFS and OS with adjuvant celecoxib plus chemotherapy vs placebo in resected colorectal cancer.

Patient who are adolescent or young adults are at higher risk of metastatic recurrence according to researchers at UC Davis Health.

Safety analysis shows sacituzumab govitecan plus pembrolizumab has a manageable profile and fewer dose reductions than chemoimmunotherapy in PD-L1+ TNBC.

Epcoritamab plus R-CHOP delivered durable remissions beyond 3 years across high-risk subgroups of patients with newly diagnosed DLBCL.

The subcutaneous formulation of amivantamab has received FDA approval for refractory, EGFR-mutant non–small cell lung cancer.

The FDA has granted regular approval to rucaparib (Rubraca) for BRCA mutation–associated metastatic castration-resistant prostate cancer.

Alexander B. Olawaiye, MD, spotlights this phase 2 study evaluating bevacizumab plus relacorilant and nab-paclitaxel in platinum-resistant ovarian cancer.

Eniluracil plus capecitabine showed signs of improved efficacy vs capecitabine alone while maintaining safety in advanced/metastatic breast cancer.

Enfortumab vedotin plus pembrolizumab is the first perioperative regimen without chemotherapy to improve both EFS and OS in cisplatin-eligible MIBC.

FOG-001 demonstrated a manageable safety profile in addition to antitumor activity that was clinically meaningful in patients with desmoid tumors.

IL-36 gamma ‘armored’ CAR T cells boost effectiveness of therapies and help eradicate solid tumors according to researchers at Roswell Park.

Maurie Markman, MD, discusses the role of decision support tools in cancer management.

Ciforadenant in combination with ipilimumab and nivolumab was safe and feasible but did not enhance activity in frontline ccRCC.

R. Lor Randall, MD, FACS, discusses findings from a phase 2 study of denosumab in patients with osteosarcoma.

The FDA has expanded the indications of 2 assays to identify patients with HER2+ breast cancer for treatment with T-DXd.

Muzastotug has been granted fast track designation by the FDA for use in combination with pembrolizumab as treatment for patients with MSS mCRC.

Proton beam therapies can result in strong outcomes for patients with throat cancer according to Mayo Clinic researchers.

Venetoclax in combination with enzalutamide displayed a favorable safety profile as a treatment regimen for mCRPC.

The first pediatric cancer progress report published by AACR identified strengths and weaknesses of contemporary pediatric cancer research.

Sacituzumab govitecan showed manageable safety vs chemotherapy in first-line TNBC, with fewer dose changes and faster AE resolution.

Anito-cel showed deepening responses in patients with relapsed or refractory myeloma enrolled in the phase 2 iMMagine-1 study.

Omitting sentinel lymph node biopsy displayed noninferiority in select older patients with hormone receptor–positive breast cancer.

The FDA approved T-DXd plus pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

The FDA has given a national priority voucher to teclistamab plus daratumumab for relapsed/refractory multiple myeloma, based on MajesTEC-3 data.

Researchers at UCSF share results about individualized breast cancer screenings from the WISDOM study.